Hubei Biocause Pharmaceutical Co., Ltd. (SHE:000627)
China · Delayed Price · Currency is CNY 1.460
-0.070 (-4.58%)
Aug 1, 2025, 3:04 PM CST
Chuy's Holdings Revenue
Hubei Biocause Pharmaceutical had revenue of 4.54B CNY in the quarter ending September 30, 2024, a decrease of -41.47%. This brings the company's revenue in the last twelve months to 40.70B, down -22.90% year-over-year. In the year 2023, Hubei Biocause Pharmaceutical had annual revenue of 48.28B, down -2.10%.
Revenue (ttm)
40.70B
Revenue Growth
-22.90%
P/S Ratio
0.18
Revenue / Employee
23.06M
Employees
1,765
Market Cap
7.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 48.28B | -1.03B | -2.10% |
| Jan 1, 2023 | 49.31B | 614.72M | 1.26% |
| Jan 1, 2022 | 48.70B | 7.57B | 18.40% |
| Dec 31, 2020 | 41.13B | -8.54B | -17.20% |
| Dec 31, 2019 | 49.67B | 19.79B | 66.25% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Merchants Bank | 295.79B |
| Ping An Insurance (Group) Company of China | 945.67B |
| Industrial Bank | 151.04B |
| CITIC Securities Company | 64.88B |
| Shanghai Pudong Development Bank | 101.05B |
| East Money Information | 12.50B |
| China Pacific Insurance (Group) | 315.25B |
| Guotai Haitong Securities | 45.79B |